Sacituzumab Govitecan vs Sacituzumab Tirumotecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline
Sacituzumab Govitecan
Marketed by Gilead Sciences and partners
NCT05089734 · Phase 3 · active, not recruiting
This was a randomized, open-label Phase 3 trial of 603 patients comparing sacituzumab govitecan to docetaxel, using overall survival (a hard clinical endpoint) as the primary measure. Although the drug showed a numerical survival advantage (11.1 vs 9.8 months), the difference did not reach statistical significance (p=0.0534), so the trial's primary comparison was not formally met despite a reasonably strong and adequately powered design.
Next expected readout: January 2027 · NCT05609968 (registry estimate)
Reported efficacy
Overall Survival (OS) (Up to 24.4 months): EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant (missed)
Result source: NCT05089734
Sacituzumab Tirumotecan
Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners
NCT05870319 · Phase 3 · active, not recruiting
This is a randomized, adequately sized (n=376) trial with an active comparator (standard chemotherapy) and a hard clinical endpoint (progression-free survival), and the result was strongly positive favoring the drug. However, the study was conducted open-label with no blinding, which limits confidence in a design that would otherwise support a top-tier grade despite the clear and statistically robust result.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT06448312 (registry estimate)
Reported efficacy
Progression-free survival (PFS) (From baseline until disease progression, death, or other protocol defined reason,up to approximately 36 months): OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001 (met)
Result source: NCT05870319
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Sacituzumab Govitecan | Sacituzumab Tirumotecan |
|---|---|---|
| PFS, median | —Trial running · NCT05609968 | —Trial running · NCT05870319 |
| OS, median | —Trial running · NCT05609968 | —Trial running · NCT05870319 |
| ORR | —Trial running · NCT05609968 | —Trial running · NCT05870319 |
| Duration of response, median | —Trial running · NCT05609968 | —Trial running · NCT05870319 |
PFS, median
- Sacituzumab Govitecan
- —Trial running · NCT05609968
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
OS, median
- Sacituzumab Govitecan
- —Trial running · NCT05609968
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
ORR
- Sacituzumab Govitecan
- —Trial running · NCT05609968
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
Duration of response, median
- Sacituzumab Govitecan
- —Trial running · NCT05609968
- Sacituzumab Tirumotecan
- —Trial running · NCT05870319
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Sacituzumab Govitecan: 1 of 4 rows · Sacituzumab Tirumotecan: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Sacituzumab Govitecan |
|---|---|
| Dropout rate | 4.8%10 mg/kga NCT01631552 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —10 mg/kga NCT01631552 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | —10 mg/kga NCT01631552 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: TROP2 · full HR+/HER2- Metastatic Breast Cancer pipeline
Sacituzumab Govitecan
Marketed by Gilead Sciences and partners
NCT03901339 · Phase 3 · completed
The trial was large and randomized, with 272 participants receiving sacituzumab govitecan and 271 receiving active physician’s-choice chemotherapy, and its independently reviewed imaging-based progression-free survival endpoint was met. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the statistically significant result.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4) (met)
Result source: NCT03901339
Sacituzumab Tirumotecan
Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06081959 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Sacituzumab Govitecan | Sacituzumab Tirumotecan |
|---|---|---|
| PFS, median | 5.5 vs 4vs Treatment of Physician's ChoiceNCT039013391 other result
| —Trial running · NCT06312176 |
| OS, median | 14.5 vs 11.2vs Treatment of Physician's ChoiceNCT03901339 | —Trial running · NCT06312176 |
| ORR | —Trial running · NCT05840211 | —Trial running · NCT06312176 |
| Clinical benefit rate | —Trial running · NCT05840211 | —Trial running · NCT06312176 |
PFS, median
- Sacituzumab Govitecan
- 5.5 vs 4vs Treatment of Physician's ChoiceNCT03901339
1 other result
- 4.3 vs 3.1 NCT03901339
- Sacituzumab Tirumotecan
- —Trial running · NCT06312176
OS, median
- Sacituzumab Govitecan
- 14.5 vs 11.2vs Treatment of Physician's ChoiceNCT03901339
- Sacituzumab Tirumotecan
- —Trial running · NCT06312176
ORR
- Sacituzumab Govitecan
- —Trial running · NCT05840211
- Sacituzumab Tirumotecan
- —Trial running · NCT06312176
Clinical benefit rate
- Sacituzumab Govitecan
- —Trial running · NCT05840211
- Sacituzumab Tirumotecan
- —Trial running · NCT06312176
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Sacituzumab Tirumotecan: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Sacituzumab Govitecan: 2 of 4 rows · Sacituzumab Tirumotecan: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Sacituzumab Govitecan |
|---|---|
| Dropout rate | n/a: no completion milestone NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Discontinued due to AEs | — NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Serious AEs | 27.6% NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Most frequent reported AEs | neutropenia 68.7% diarrhoea 60.8% nausea 58.6% NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Sacituzumab Govitecan
show 1 more result
Breast Cancer
Shared mechanism: TROP2 · full Breast Cancer pipeline
Sacituzumab Govitecan
Marketed by Gilead Sciences and partners
NCT03901339 · Phase 3 · completed
The trial was large and randomized, with 272 participants receiving sacituzumab govitecan and 271 receiving active physician’s-choice chemotherapy, and its independently reviewed imaging-based progression-free survival endpoint was met. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the statistically significant result.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4) (met)
Result source: NCT03901339
Sacituzumab Tirumotecan
Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners
NCT05347134 · Phase 3 · active, not recruiting
This was a randomized, adequately sized (n=254) phase 3 trial with an active chemotherapy comparator and a hard clinical endpoint (progression-free survival, reviewed independently), and it clearly succeeded, showing a large PFS benefit for sac-TMT over chemotherapy. However, the trial was open-label with no blinding of patients or investigators, which limits confidence in any endpoints subject to subjective influence, so despite the strong result this design element keeps the grade at moderate rather than the highest tier.
Next expected readout: December 2026 · NCT06081959 (registry estimate)
Reported efficacy
Progression-free survival (PFS) (up to 24 months): OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001 (met)
Result source: NCT05347134
Results for Breast Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Sacituzumab Govitecan
show 3 more results
show 2 more results
show 1 more result
show 1 more result
+ 13 further endpoints in the CSV export.
Available safety results
Sacituzumab Govitecan
| Dropout rate | n/a: no completion milestone NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 2 more resultsn/a: no completion milestone NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3 4.8%10 mg/kg NCT01631552 · Phase 1/2 |
|---|---|
| Discontinued due to AEs | — NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 2 more results— NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3 —10 mg/kg NCT01631552 · Phase 1/2 |
| Serious AEs | 27.6% NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 2 more results26.7% NCT02574455 · Phase 3 · monotherapy · Breast Cancer · phase 3 —10 mg/kg NCT01631552 · Phase 1/2 |
| Most frequent reported AEs | neutropenia 68.7% diarrhoea 60.8% nausea 58.6% NCT03901339 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more result |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sacituzumab Govitecan's landscape · Sacituzumab Tirumotecan's landscape